SpringWorks Therapeutics (NASDAQ:SWTX), Inc. is a clinical‐stage biopharmaceutical company dedicated to developing precision therapies for patients living with rare diseases and cancer. Leveraging its expertise in targeted molecular pathways, the company focuses on advancing novel small‐molecule inhibitors and biologics designed to address underlying genetic drivers. SpringWorks’ mission is to translate cutting‐edge science into effective, well‐tolerated treatments that fill critical unmet medical needs.
The company’s pipeline features several late‐stage programs, including mirdametinib (PD-0325901), a selective MEK inhibitor being evaluated for neurofibromatosis type 1 plexiform neurofibromas, and nirogacestat, an oral gamma secretase inhibitor in development for desmoid tumors. In addition, SpringWorks is exploring seclidemstat, an LSD1 inhibitor targeting Ewing sarcoma and other hematologic malignancies. These core assets stem from strategic collaborations and in-licensing agreements, positioning SpringWorks to advance multiple registrational studies in both the United States and Europe.
Founded in 2017 as a spin-out from a global pharmaceutical company, SpringWorks is headquartered in Stamford, Connecticut, with research and development facilities in North America and Europe. The company conducts multi‐center clinical trials across the U.S., Canada, Australia and key European markets. By partnering with academic institutions and patient advocacy groups, SpringWorks ensures broad access to clinical programs and collaborates on real‐world evidence initiatives.
Under the leadership of President and Chief Executive Officer Saqib Islam and Chief Medical Officer Jan Ewbank, SpringWorks maintains a seasoned management team with deep experience in oncology, rare diseases and clinical development. The board of directors comprises industry veterans and patient advocacy representatives, guiding strategic decision‐making as SpringWorks advances its mission to deliver transformative therapies for underserved patient populations.
